MDGEF (Medigene AG) Total Liabilities: $9.85 Mil (As of Jun. 2024)


MDGEF Medigene AG MDGEF
12 GF Score
Price $2.59
View Full Analysis

What is Medigene AG Total Liabilities?

Medigene AG MDGEF 12 Total Liabilities is $9.85 Mil as of Jun. 2024. GuruFocus rates MDGEF with a GF Score™ of 12/100.

Medigene AG's Total Liabilities for the quarter that ended in Jun. 2024 was $9.85 Mil.

Medigene AG's quarterly Total Liabilities declined from Jun. 2023 ($12.99 Mil) to Dec. 2023 ($11.61 Mil) and declined from Dec. 2023 ($11.61 Mil) to Jun. 2024 ($9.85 Mil).

Medigene AG's annual Total Liabilities declined from Dec. 2021 ($16.56 Mil) to Dec. 2022 ($15.52 Mil) and declined from Dec. 2022 ($15.52 Mil) to Dec. 2023 ($11.61 Mil).

Medigene AG Total Liabilities Historical Data

* Premium members only.

The historical data trend for Medigene AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigene AG Total Liabilities Chart

Medigene AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.44 26.27 16.56 15.52 11.61

Medigene AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.35 15.52 12.99 11.61 9.85
MDGEF
12GF Score
Medigene AG MDGEF
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigene AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Medigene AG's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.829+(2.22+1.564
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=11.61

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=34.587-22.974
=11.61

Medigene AG's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.031+(1.733+1.085
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=9.85

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=31.012-21.163
=9.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $9.85 Mil mean?
Medigene AG (MDGEF) has a Total Liabilities of $9.85 Mil as of Jun. 2024. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Medigene AG and its competitors.
Is Medigene AG's Total Liabilities too high?
Medigene AG's current Total Liabilities is $9.85 Mil. Overall, Medigene AG has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medigene AG's Total Liabilities compare to VRTX and REGN?
Medigene AG's Total Liabilities of $9.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Medigene AG and its competitors. Medigene AG's current Total Liabilities is $9.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigene AG stock overvalued right now?
Medigene AG (MDGEF) has a current Total Liabilities of $9.85 Mil. The current Total Liabilities is $9.85 Mil. Medigene AG's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Medigene AG (MDGEF), the current Total Liabilities is $9.85 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medigene AG Business Description

Address Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
12GF Score

Get the complete analysis for MDGEF

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.59
Price